Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update

Simple item page
dc.contributor.authorKarnes, Jason H.
dc.contributor.authorRettie, Allan E.
dc.contributor.authorSomogyi, Andrew A.
dc.contributor.authorHuddart, Rachel
dc.contributor.authorFohner, Alison E.
dc.contributor.authorFormea, Christine M.
dc.contributor.authorLee, Ming Ta Michael
dc.contributor.authorLlerena, Adrian
dc.contributor.authorWhirl-Carrillo, Michelle
dc.contributor.authorKlein, Teri E.
dc.contributor.authorPhillips, Elizabeth J.
dc.contributor.authorMintzer, Scott
dc.contributor.authorGaedigk, Andrea
dc.contributor.authorCaudle, Kelly E.
dc.contributor.authorCallaghan, John T.
dc.contributor.departmentMedicine, School of Medicineen_US
dc.date.accessioned2023-05-03T16:57:41Z
dc.date.available2023-05-03T16:57:41Z
dc.date.issued2021
dc.description.abstractPhenytoin is an antiepileptic drug with a narrow therapeutic index and large interpatient pharmacokinetic variability, partly due to genetic variation in CYP2C9. Furthermore, the variant allele HLA-B*15:02 is associated with an increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in response to phenytoin treatment. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for the use of phenytoin based on CYP2C9 and/or HLA-B genotypes (updates on cpicpgx.org).en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationKarnes JH, Rettie AE, Somogyi AA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther. 2021;109(2):302-309. doi:10.1002/cpt.2008en_US
dc.identifier.urihttps://hdl.handle.net/1805/32784
dc.language.isoen_USen_US
dc.publisherWileyen_US
dc.relation.isversionof10.1002/cpt.2008en_US
dc.relation.journalClinical Pharmacology & Therapeuticsen_US
dc.rightsPublisher Policyen_US
dc.sourcePMCen_US
dc.subjectPhenytoinen_US
dc.subjectPharmacogeneticsen_US
dc.subjectFosphenytoinen_US
dc.subjectStevens-Johnson syndromeen_US
dc.subjectToxic epidermal necrolysisen_US
dc.titleClinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Updateen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
nihms-1656848.pdf
Size:
683.83 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles
Department of Medicine Works